Stock Market Stallions
BioNano Genomics Inc (NASDAQ: BNGO) has had a remarkable year of trading, gaining over 979% over the past two months. The company operates in the analytical instruments field, in particular cytogenomics. Simply put, this is the detection of genetic disorders by analyzing the variances in chromosomes.… Read more
Vaxart Inc (NASDAQ: VXRT) has seen a remarkable year on Wallstreet after investors rallied behind its experimental COVID-19 vaccine. VXRT stock has gained some serious ground over the past year, surging over 1,559% YTD. Unlike other COVID-19 vaccine candidates, the vaccine is administered orally and can be stored at room temperature.… Read more
Sorrento Therapeutics Inc (NASDAQ: SRNE) has recaptured the attention of investors as analysts remain confident in the companies 12 month outlook. The stock has performed well as of late, posting a 29% gain over the past month of trading. Furthermore, the average 12 month price target amongst Wallstreet analysts is $29.67 a share.… Read more
Social Capital Hedosophia (NYSE: IPOC) are set to close in on their merger with Clover Health in early 2021. Evidently, this has caused a strong upswing in investor momentum in IPOC’s trading price. IPOC has gained 33% over the past week of trading and 66% for the month of December.… Read more
The past two weeks have seen a large shift in investor sentiment towards these two key COVID vaccine pioneers. Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) have seen a recent surge in the share price. The companies saw an increase of 26.52% (NVAX) and 38.26% (MRNA) respectively over the past week of trading.… Read more
Novavax, Inc.(NASDAQ: NVAX) has seen an incredible year in stock price growth, increasing 1,1711.50% YTD. The companies COVID-19 vaccine saw the market rally behind NVAX, posting a 52 week high in August of $189.40. The company announced yesterday an agreement of principle with the Commonwealth of Australia for Acquisition of 40 million doses of NVX-CoV2373.… Read more
iBio inc. (NYSE:IBIO) rose to popularity amongst the investor community as they announced their intentions to develop a COVID-19 vaccine. The stock is currently trading 586% higher since the beginning of 2020. However since July, iBio stock has been on a downward slope which has since found a new equilibrium at $2.… Read more
Sorrento Therapeutics (NASDAQ: SRNE) was lacking direction as short-sellers brought down the stock after most positive announcements. However, the green light from the FDA allows the bulls to lay down the trackwork. The clear path is promising, but the volatility is making it difficult for investors to enter.… Read more
CVS Health (NASDAQ: CVS) stock has been going on a rollercoaster ride in 2020 so far. The start of the year was promising as the healthcare giant hit 52-week highs. Unfortunately, COVID-19 sent CVS spiraling down. Investors are currently unsure what is in store for CVS come 2021 and beyond.… Read more
Will Teva stock recover from the recent bloodbath? It is the big question institutions and retail investors are asking. On one end, investors believe the lawsuit and stagnating financials will cripple Teva. Conversely, the bullish hedge funds argue that Teva holds value in the long-term. Thus, today’s article will breakdown the recent sell-off, which institutions are bullish, and the likelihood of a recovery.… Read more
Sorrento Therapeutics (NASDAQ: SRNE) is putting on a volatility show this week. The bulls were leading the charge at the start of the week but took a big rest on Wednesday, which saw SRNE pullback by 12%. All bullish hope seemed lost. However, today the FDA gave Sorrento the green light to begin phase I COVID-19 trials.… Read more
Inovio (NASDAQ:INO) is set to open 10% higher this morning after the promising address by CEO & President Dr. Joseph Kim on the H.C Wainwright 22nd Annual Investment Conference. Dr. Kim advised that the initiation of Phase 2 trials for their COVID-19 vaccine INO-4800 is on track to commence later this month.… Read more
Biomerica (NASDAQ:BMRA) is set to release Q2 earnings this Friday, with experts forecasting an expected EPS of -$0.05. This would mark a 37% improvement for Q2 Earnings Year on Year. The medical diagnostic manufacturer has thrived on the opportunity this year to develop a viable COVID-19 test.… Read more